Cardiology
Novel Insights from Clinical Experience
Transcatheter Closure of a Ventricular Septal Defect following Myectomy for Hypertrophic Obstructive CardiomyopathySpies C.a · Ujivari F.b · Schraeder R.baRush University Medical Center, Section of Cardiology, Chicago, Ill., USA; bMarkuskrankenhaus, Medizinische Klinik III – Cardioangiologisches Centrum Bethanien, Frankfurt am Main, Deutschland
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: January 13, 2008
Accepted: January 17, 2008
Published online: June 25, 2008
Issue release date: November 2008
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Abstract
Post-operative ventricular septal defect (VSD) following septal myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM) is a rare complication which may warrant closure. Repeat early sternotomy for surgical closure of the VSD seems undesirable and transcatheter VSD closure may be a valid alternative. We report the case of successful closure of a 10-mm VSD following surgical therapy for HOCM using an Amplatzer Muscular VSD Occluder.
© 2008 S. Karger AG, Basel
Related Articles:
References
- Schulte HD, Bircks W, Lösse B: Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM). Z Kardiol 1987;76(suppl 3):145–151.
- Temeck BK, Katz NM, Wallace RB: An approach to reoperative median sternotomy. J Card Surg 1990;5:14–25.
- Chessa M, Carminati M, Cao QL, Butera G, Giusti S, Bini RM, Hijazi ZM: Transcatheter closure of congenital and acquired muscular ventricular septal defects using the Amplatzer device. J Invasive Cardiol 2002;14:322–327.
- Walsh MA, Coleman DM, Oslizlok P, Walsh KP: Percutaneous closure of postoperative ventricular septal defects with the Amplatzer device. Catheter Cardiovasc Interv 2006;67:445–451.
- de Wolf D, Taeymans Y, Suys B, Matthys D, Van Nooten G: Percutaneous closure of a ventricular septal defect after surgical treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2006;132:173–174.
- Thanopoulos BD, Tsaousis GS, Konstadopoulou GN, Zarayelyan AG: Transcatheter closure of muscular ventricular septal defects with the amplatzer ventricular septal defect occluder: initial clinical applications in children. J Am Coll Cardiol 1999;33:1395–1399.
- Holzer R, Latson L, Hijazi ZM: Device closure of iatrogenic membranous ventricular septal defects after prosthetic aortic valve replacement using the Amplatzer membranous ventricular septal defect occluder. Catheter Cardiovasc Interv 2004;62:276–280.
- Aroney CN, Goh TH, Hourigan LA, Dyer W: Ventricular septal rupture following nonsurgical septal reduction for hypertrophic cardiomyopathy: treatment with percutaneous closure. Catheter Cardiovasc Interv 2004;61:411–414.
Article / Publication Details
Received: January 13, 2008
Accepted: January 17, 2008
Published online: June 25, 2008
Issue release date: November 2008
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 0
ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)
For additional information: https://www.karger.com/CRD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
